Jan 9 (Reuters) - The U.S. Federal Trade ‌Commission won

a ruling on Friday blocking Edwards Lifesciences' ( EW ) acquisition ​of

JenaValve Technology, court records showed.

The FTC sued in ‍August, saying the deal would ⁠decrease

competition in ⁠the market for a device meant to treat a

potentially fatal ‌heart condition.

"This is ​a major win for the Trump-Vance administration,"

said FTC spokesperson Joe Simonson. "We will never ⁠stop working

to promote ‍innovation, ​lowering healthcare costs, and saving

American lives."

A spokesperson for Edwards did not immediately comment.

Judge Rudolph ‍Contreras in Washington said he had granted the

FTC's request, but the opinion explaining his reasoning will be

sealed until the companies have a chance to propose a public

version that ​protects ‍their confidential information.

In its lawsuit, the FTC said Edwards and JenaValve are the

only ​two companies in the United States conducting clinical

trials for the use of transcatheter aortic valve replacement

systems to treat aortic regurgitation, a condition in which the

heart's aortic valve does not close properly.

Edwards' ​flagship TAVR system for patients with aortic

stenosis brought in $1.15 billion in the third quarter.